Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Harvard Business School
Citi
Deloitte
Medtronic
Teva
QuintilesIMS
Chubb

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DYNACIN

« Back to Dashboard

Clinical Trials for Dynacin

Trial ID Title Status Sponsor Phase Summary
NCT01048983 Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn National Cancer Institute (NCI) Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01048983 Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn M.D. Anderson Cancer Center Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01173692 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Active, not recruiting National Cancer Institute (NCI) Phase 2 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01173692 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Active, not recruiting M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01219673 Symptom Burden in Head and Neck Cancer Terminated National Cancer Institute (NCI) Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, and minocycline when given alone or in combination. Researchers want to learn about the safety and level of effectiveness of these drugs in controlling symptoms, such as the side effects of chemoradiation, when given to patients with head and neck cancer.
NCT01219673 Symptom Burden in Head and Neck Cancer Terminated M.D. Anderson Cancer Center Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, and minocycline when given alone or in combination. Researchers want to learn about the safety and level of effectiveness of these drugs in controlling symptoms, such as the side effects of chemoradiation, when given to patients with head and neck cancer.
NCT01283997 Prevention of Treatment Induced Neuropathy in Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 2 The goal of this clinical research study is to see if Minocin® (minocycline) can help to control nerve damage that causes numbness and tingling in the hands and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dynacin

Condition Name

Condition Name for Dynacin
Intervention Trials
Head And Neck Cancer 2
Myeloma 2
Lung Cancer 2
Pain, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dynacin
Intervention Trials
Lung Neoplasms 3
Carcinoma, Non-Small-Cell Lung 3
Neoplasms, Plasma Cell 2
Multiple Myeloma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dynacin

Trials by Country

Trials by Country for Dynacin
Location Trials
United States 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dynacin
Location Trials
Texas 11
Missouri 1
Michigan 1
Indiana 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dynacin

Clinical Trial Phase

Clinical Trial Phase for Dynacin
Clinical Trial Phase Trials
Phase 2 10
Phase 1/Phase 2 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dynacin
Clinical Trial Phase Trials
Active, not recruiting 7
Recruiting 2
Terminated 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dynacin

Sponsor Name

Sponsor Name for Dynacin
Sponsor Trials
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 10
Indiana University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dynacin
Sponsor Trials
Other 22
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Farmers Insurance
Citi
Queensland Health
Moodys
McKinsey
Covington
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.